Introduction {#S0001}
============

Most *Escherichia coli* strains that colonize the human intestines rarely cause illness in healthy individuals. However, a number of pathogenic strains can cause intestinal or other diseases in healthy, as well as immunocompromised individuals.[@CIT0001] Commensal *E. coli* strains can evolve into highly adapted pathogens capable of inducing diseases following the acquisition of a combination of mobile genetic elements, including virulence genes.[@CIT0001]--[@CIT0003]

The occurrence of multidrug resistant (MDR) *E. coli* strains has increased in recent years, leading to a severe problem in healthcare settings, especially in developing countries.[@CIT0004]--[@CIT0006] MDR *E. coli* strains complicate treatment, as they require prolonged hospitalization and antibiotic treatment and increase the need of surgery, which eventually increase mortality.[@CIT0007],[@CIT0008]

*E. coli* strains have been well documented in healthcare settings in western China; however, their characterization has often been limited to phenotypic tests and the identification of resistance genes,[@CIT0009]--[@CIT0013] with limited information regarding their virulence factors. Previously, we examined the virulence gene profiles of 13 diarrheagenic *E. coli* (DEC) strains isolated from a hospital in western China, as well as the molecular characteristics of their genes.[@CIT0014] Here, we characterized *E. coli* strains from a hospital in western China and determined their virulence and antimicrobial resistance potential, to better understand the prevalence of virulence genes and antimicrobial resistance in clinical *E.coli* isolates. This study emphasizes the importance of preventing the spread of *E.coli* isolates that harbor both antimicrobial resistance and virulence genes in the clinical setting.

Methods {#S0002}
=======

Bacterial Isolates {#S0002-S2001}
------------------

A total of 97 non-duplicated clinical *E. coli* isolates were collected from 97 different patients in various departments (gastroenterology, urology, endocrinology, neurosurgery, and other wards) of the First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China from 2015 to 2016. The isolates were identified using standard laboratory methods and the ATB New system (bioMérieux, Lyons, France). Patients who satisfied the following three criteria were included in the analysis: 1) age \>18 years; 2) suspected of having an infection, based on their clinical symptoms (e.g. fever, abdominal pain, nausea, vomiting, dehydration and tenesmus); and 3) their bacterial culture yielded *E. coli*. The *E. coli* isolates were collected from biofluid samples including blood, urine, sputum, wound exudates and abscesses. Each isolate was further verified by PCR amplification of a 369-bp internal control region from the *E. coli* marker gene, *alr*.[@CIT0015] All bacterial strains were stored at −80 °C and were grown on MacConkey Agar (Oxoid, Hampshire, UK).

The study protocol was approved by the Ethics Committee of Chengdu Medical College, in accordance with the Helsinki declaration. In all cases, the patients or their family members were informed and their written consents was obtained.

Detection of Adherence and Virulence Genes {#S0002-S2002}
------------------------------------------

All *E. coli* isolates were subjected to PCR to detect 12 adherence (*bfp, daaD, daaE, fimC, fimH, aggA, aafA, agg3A, agg4A, lpfA, sfa*, and *pap*) and 27 virulence (*aggR, pic, astA, stx1, stx2, eae, ipaH, est, elt, irp2, fyuA, escJ, escN, escV, espP, nleB, nleE, ent/espL2, cnf1, cnf2, cdt-I, cdt-II, invE, hlyA, pet, sat*, and *subAB*) genes. The primers used to amplify these genes are listed in [Table 1](#T0001){ref-type="table"}.Table 1Gene Primers Used in This StudyGenePrimer Sequence (5´-3´)PCR Product (bp)Reference*alr*F: CTGGAAGAGGCTAGCCTGGACGAG\
R: AAAATCGCCACCGGTGGAGCGATC369[@CIT0015]*bfp*F: GACACCTCATTGCTGAAGTCG\
R: CCAGAACACCTCCGTTATGC324[@CIT0055]*daaD*F: TGAACGGGAGTATAAGGAAGATG\
R: GTCCGCCATCACATCAAAA444[@CIT0056]*daaE*F: GAACGTTGGTTAATGTGGGGTAA\
R: TATTCACCGGTCGGTTATCAGT542[@CIT0057]*fimC*F: GGGTAGAAAATGCCGATGGTG\
R: CGTCATTTTGGGGGTAAGTG477[@CIT0058]*fimH*F: CGAGTTATTACCCTGTTTGCTG\
R: ACGCCAATAATCGATTGCAC878[@CIT0059]*aggA*F: GCTAACGCTGCGTTAGAAAGACC\
R: GGAGTATCATTCTATATTCGCC421[@CIT0059]*aafA*F: ATGTATTTTTAGAGGTTGAC\
R: TATTATATTGTCACAAGCTC518[@CIT0060]*agg3A*F: GTATCATTGCGAGTCTGGTATTCAG\
R: GGGCTGTTATAGAGTAACTTCCAG462[@CIT0059]*agg4A*F: TGAGTTGTGGGGCTAYCTGGACACC\
R: ATAAGCCGCCAAATAAGC169[@CIT0041]*lpfA*F: AGGCGGTGCATTCACTCTGGCATCT\
R: CCGCGTCGATAGCGGTATAGGCAGA446[@CIT0061]*sfa*F: CTCCGGAGAACTGGGTGCATCTTAC\
R: CGGAGGAGTAATTACAAACCTGGCA408[@CIT0059]*pap*F: GACGGCTGTACTGCAGGGTGTGGCG\
R: ATATCCTTTCTGCAGGGATGCAATA328[@CIT0059]*aggR*F: ACGCAGAGTTGCCTGATAAAG\
R: AATACAGAATCGTCAGCATCAGC400[@CIT0055]*pic*F: GGGTATTGTCCGTTCCGAT\
R: ACAACGATACCGTCTCCCG1176[@CIT0062]*astA*F: CCATCAACACAGTATATCCGA\
R: GGTCGCGAGTGACGGCTTTGT111[@CIT0059]*stx1*F: CGATGTTACGGTTTGTTACTGTGACAGC\
R: AATGCCACGCTTCCCAGAATTG244[@CIT0055]*stx2*F: GTTTTGACCATCTTCGTCTGATTATTGAG\
R: AGCGTAAGGCTTCTGCTGTGAC324[@CIT0055]*eae*F: TGAGCGGCTGGCATGAGTCATAC\
R: TCGATCCCCATCGTCACCAGAGG241[@CIT0063]*ipaH*F: GTTCCTTGACCGCCTTTCCGATACCGTC\
R: AAAATCGCCACCGGTGGAGCGATC619[@CIT0064]*est*F: ATTTTTCTTTCTGTATTGTCTT\
R: CACCCGGTACAGGCAGGATT190[@CIT0065]*elt*F: GGCGACAGATTATACCGTGC\
R: CGGTCTCTATATTCCCTGTT450[@CIT0065]*irp2*F: AAGGATTCGCTGTTACCGGAC\
R: TCGTCGGGCAGCGTTTCTTCT264[@CIT0066]*fyuA*F: TGATTAACCCCGCGACGGGAA\
R: CGCAGTAGGCACGATGTTGTA785[@CIT0027]*escJ*F: CACTAAGCTCGATATATAGAACCC\
R: GTCAATGTTGATGTCGTATCTAAG824[@CIT0040]*escN*F: CGCCTTTTACAAGATAGAAC\
R: CATCAAGAATAGAGCGGAC854[@CIT0067]*escV*F: GATGACATCATGAATAAACTC\
R: GCCTTCATATCTGGTAGAC2128[@CIT0040]*espP*F: AAACAGCAGGCACTTGAACG\
R: GGAGTCGTCAGTCAGTAGAT1830[@CIT0062]*nleB*F: GGAAGTTTGTTTACAGAGACG\
R: AAAATGCCGCTTGATACC297[@CIT0068]*nleE*F: GTATAACCAGAGGAGTAGC\
R: GATCTTACAACAAATGTCC260[@CIT0068]*ent/espL2*F: GAATAACAATCACTCCTCACC\
R: TTACAGTGCCCGATTACG233[@CIT0068]*cnf1*F: GGCGACAAATGCAGTATTGCTTGG\
F: GACGTTGGTTGCGGTAATTTTGGG552[@CIT0062]*cnf2*F: GTGAGGCTCAACGAGATTATGCACTG\
R: CCACGCTTCTTCTTCAGTTGTTCCTC839[@CIT0062]*cdt-Ⅰ*F: CAATAGTCGCCCACAGGA\
R: ATAATCAAGAACACCACCAC412[@CIT0069]*cdt-Ⅱ*F: GAAAGTAAATGGAATATAAATGTCCG\
R: TTTGTGTTGCCGCCGCTGGTGAAA556[@CIT0069]*invE*F:CGATCAAGAATCCCTAACAGAAGAATCAC\
R: CGATAGATGGCGAGAAATTATATCCCG766[@CIT0055]*hlyA*F: GCATCATCAAGCGTACGTTCC\
R: AATGAGCCAAGCTGGTTAAGCT533[@CIT0066]*pet*F: TTTCCAGCACTTCCTGTTCC\
R: ATTTCCAACGTCTACGCCAT297[@CIT0070]*sat*F: GCAGCAAATATTGATATATCA\
R: GTTGTTGACCTCAGCAAGGAA2913[@CIT0040]*subAB*F: TATGGCTTCCCTCATTGCC\
R: TATAGCTGTTGCTTCTGACG556[@CIT0071]

Antimicrobial Susceptibility Testing {#S0002-S2003}
------------------------------------

The minimum inhibitory concentrations (MICs) of 24 antimicrobial agents against the *E. coli* isolates were determined by agar dilution methods, according to the 2019 Clinical and Laboratory Standards Institute guidelines.[@CIT0016] The following 24 antimicrobial agents were tested: sulfonamide, doxycycline, tetracycline, cefotaxime, ampicillin, ticarcillin, nalidixic acid, cefoperazone, piperacillin, gentamicin, ciprofloxacin, levofloxacin, ofloxacin, tobramycin, cefoxitin, ceftazidime, minocycline, aztreonam, kanamycin, amikacin, chloramphenicol, meropenem, imipenem, and ertapenem. The results were used to classify the isolates as resistant or susceptible to a particular antibiotic using standard reference values.[@CIT0016]

Results {#S0003}
=======

Detection of *E. coli* Adherence and Virulence Genes {#S0003-S2001}
----------------------------------------------------

The presence of 12 adherence genes and 27 toxin-encoding genes was examined in all *E. coli* strains by PCR. As shown in [Figure 1](#F0001){ref-type="fig"}, the detection rate of *fimC, irp2, fimH, fyuA, lpfA, hlyA, sat*, and *cnf1* in the isolated *E. coli* strains was 93.81, 92.78, 91.75, 84.54, 41.24, 32.99, 28.86, and 7.22%, respectively. All isolates were negative for the other genes tested (*bfp, daaD, daaE, aggA, aafA, agg3A, agg4A, sfa, pap, aggR, pic, astA, stx1, stx2, eae, ipaH, est, elt, escJ, escN, escV, espP, nleB, nleE, ent/espL2, cnf2, cdt-I, cdt-II, invE, pet*, and *subAB*).Figure 1Frequency of virulence genes among *E.coli* isolates.

Different combinations of multiple virulence genes were detected in the *E. coli* isolates. The number of virulence genes in each isolate and the specific virulence gene combinations are shown in [Table 2](#T0002){ref-type="table"}. Two or more different virulence genes were identified in ninety-five (97.94%) isolates. Of these, 44 (45.37%) isolates simultaneously harbored five virulence genes, 24 (24.74%) isolates harbored four virulence genes, 17 (17.53%) isolates harbored six virulence genes, five (5.15%) isolates harbored three virulence genes, two (2.06%) isolates harbored two virulence genes, two (2.06%) isolates harbored seven virulence genes, and only one (1.03%) isolate harbored eight virulence genes.Table 2Distribution of Virulence Genes Among *E. coli* IsolatesNo. of Virulence GenesVirulence Genes ProfileNo. (%) of Bacterial StrainTotal No. (%)0 genes2(2.06)2(2.06)2 genes*fimC, fimH*1(1.03)2(2.06)*irp2, fyuA*1(1.03)3 genes*fimC, fimH, lpfA,*2(2.06)5(5.15)*fimC, lpfA, sat*1(1.03)*fimC, irp2, fyuA*1(1.03)*irp2, fyuA, lpfA*1(1.03)4 genes*fimC, fimH,irp2, fyuA*14(14.44)24(24.74)*fimC, fimH, irp2, lpfA*4(4.12)*fimC,irp2, fyuA, lpfA,*2(2.06)*fimH, irp2, fyuA, hlyA*2(2.06)*fimC, fimH, lpfA, hlyA*1(1.03)*fimC, fimH, hlyA, irp2*1(1.03)5 genes*fimC, fimH, irp2, fyuA, lpfA*19(19.59)44 (45.37)*fimC, fimH, irp2, fyuA, sat*12(12.38)*fimC, fimH, irp2, fyuA, hlyA*10(10.31)*fimC, fimH, irp2, lpfA, hlyA*2(2.06)*fimC, fimH, irp2, fyuA,cnf1*1(1.03)6 genes*fimC, fimH, irp2, fyuA, hlyA, sat*7(7.23)17(17.53)*fimC, fimH,irp2,fyuA,lpfA, sat*4(4.12)*fimC, fimH, irp2, fyuA,hlyA,cnf1*3(3.09)*fimC, fimH, irp2, fyuA, lpfA,hlyA*2(2.06)*fimC,fimH,irp2,lpfA,hlyA,sat*1(1.03)7 genes*fimC,fimH,irp2,fyuA,hlyA,sat,cnf1*2(2.06)2(2.06)8 genes*fimC, fimH,irp2, fyuA, lpfA,hlyA sat, cnf1*1(1.03)1(1.03)

Resistance to Antimicrobial Agents {#S0003-S2002}
----------------------------------

The 24 most commonly used antimicrobials in Chinese practice clinical were used in this study to test the antibiotic resistance of the 97 *E. coli* isolates,[@CIT0014],[@CIT0018]--[@CIT0020] including penicillin (ampicillin, ticarcillin, piperacillin), cephems (cefoxitin, cefoperazone, cefotaxime, ceftazidime), monobactams (aztreonam), carbapenems (meropenem, imipenem, ertapenem), aminoglycosides (tobramycin, kanamycin, gentamicin, amikacin, chloramphenicol), tetracyclines (deoxycycline, minocycline, tetracycline), quinolones (levofloxacin, ofloxacin, nalidixic acid, ciprofloxacin).[@CIT0016] The resistance profiles of the *E. coli* isolates against these 24 antibiotics are detailed in [Table 3](#T0003){ref-type="table"}. The isolates exhibited a high degree of resistance, especially against sulfonamide (97.94%), ampicillin (94.85%), ticarcillin (90.72%), nalidixic acid (90.72%), tetracycline (81.44%), doxycycline (78.49%), ciprofloxacin (70.10%), ofloxacin (68.04%), cefotaxime (68.04%), and levofloxacin (60.82%). Furthermore, all *E. coli* isolates were susceptible to meropenem and imipenem. The sensitivity rate of the *E. coli* strains to ertapenem, amikacin, cefoxitin, ceftazidime, aztreonam, and chloramphenicol was 92.79, 88.66, 74.22, 67.01, 67.01, and 64.95%, respectively.Table 3Antimicrobial Susceptibility of *E. coli* Clinical IsolatesAntimicrobial AgentResistant n (%)Intermediate n (%)Susceptible n (%)Sulfonamide95 (97.94)---2 (2.06)Ampicillin92 (94.85)0(0)5 (5.15)Ticarcillin88 (90.72)2 (2.06)7 (7.23)Nalidixic acid88 (90.72)---9 (9.28)Tetracycline79 (81.44)1 (1.03)17 (17.53)Doxycycline73 (78.49)4 (4.12)20 (20.62)Ciprofloxacin68 (70.10)2 (2.06)27 (27.84)Ofloxacin66 (68.04)2 (2.06)29 (29.90)Cefotaxime66 (68.04)4 (4.12)37 (38.14)Levofloxacin59 (60.82)10 (10.31)28 (28.87)Piperacillin58 (59.79)19 (19.59)20 (20.62)Cefoperazone51 (52.58)18 (18.55)28 (28.87)Gentamicin51 (52.58)4 (4.12)42 (43.30)Kanamycin39 (40.21)1 (1.03)57 (58.76)Tobramycin39 (40.21)17 (17.53)41 (42.26)Chloramphenicol33 (34.02)1 (1.03)63 (64.95)Minocycline33 (34.02)13 (13.40)51 (52.58)Aztreonam28 (28.87)4 (4.12)65 (67.01)Ceftazidime21 (21.65)11 (11.34)65 (67.01)Cefoxitin17 (17.53)8 (8.25)72 (74.22)Amikacin8 (8.25)3 (3.09)86 (88.66)Ertapenem3 (3.09)4 (4.12)90 (92.79)Meropenem0(0)0(0)97 (100)Imipenem0(0)0(0)97 (100)

Importantly, all isolates were resistant to at least three different classes of antimicrobial agents and were considered as multidrug resistant.[@CIT0017] Of the 97 MDR *E. coli* isolates, five (5.16%), one (1.03%), one (1.03%), three (3.09%), three (3.09%), six (6.19%), nine (9.28%), six (6.19%), nine (9.28%), twelve (12.37%), nine (9.28%), eight (8.25%), eight (8.25%), four (4.12%), three (3.09%), two (2.06%), three (3.09%), two (2.06%), and three (3.09%) isolates exhibited resistance to 3--21 types of antibiotics, respectively, as shown in [Table 4](#T0004){ref-type="table"} and [Figure 2](#F0002){ref-type="fig"}.Table 4Number of *E. coli* Isolates Resistant to Different Classes of AntibioticsDifferent classes of antibiotics3456789101112131415161718192021Isolatesn51133696912988432323%5.161.031.033.093.096.199.286.199.2812.379.288.258.254.123.092.063.092.063.09 Figure 2Number of *E. coli* isolates resistant to different classes of antimicrobial agents.

Frequency of Virulence Gene Occurrence in Isolated *E. coli* Strains Exhibiting Antimicrobial Resistance {#S0003-S2003}
--------------------------------------------------------------------------------------------------------

The frequencies of virulence gene occurrence in isolated *E. coli* strains exhibiting antimicrobial resistance are detailed in [Table 5](#T0005){ref-type="table"}. The frequencies for *fimC, irp2*, and *fimH* among the resistant *E. coli* isolates were nearly \> 90%, whereas that of *fyuA* was \> 80%. Moreover, the frequencies of *lpfA, hlyA, sat*, and *cnf1* in the resistant isolates were higher than 40, 30, 20, and 5%, respectively.Table 5Frequency of Virulence Genes Among Antibiotic Resistant *E. coli* IsolatesAntibiotic (n)Virulence Genes, n (%)*fimCirp2fimHfyuAlpfAhlyAsatcnf1*Sulfonamide (95)89 (93.68)88 (92.63)88 (92.63)80 (84.21)39 (41.05)32 (33.68)27 (28.42)7 (7.37)Ampicillin (92)87 (94.56)85 (92.39)85 (92.39)77 (83.69)38 (41.30)32 (34.78)25 (27.17)7 (7.61)Ticarcillin (88)84 (95.45)82 (93.18)83 (94.32)74 (84.09)37 (42.05)32 (36.36)25 (28.41)7 (7.95)Nalidixic acid (88)84 (95.45)82 (93.18)84 (95.45)74 (84.09)38 (43.18)32 (36.36)27 (30.68)7 (7.95)Tetracycline (79)75 (94.94)75 (94.94)74 (93.67)68 (86.07)33 (41.77)25 (31.65)22 (27.85)5 (6.32)Deoxycycline (73)68 (93.15)68 (93.15)67 (91.78)63 (86.30)30 (41.10)23 (31.51)20 (27.40)5 (6.85)Ciprofloxacin (68)67 (98.53)65 (95.59)67 (98.53)59 (86.76)28 (38.36)23 (33.82)22 (32.35)6 (8.82)Ofloxacin (66)65 (98.48)63 (95.45)65 (98.48)57 (86.36)26 (39.39)24 (36.36)21 (31.82)6 (9.09)Cefotaxime (66)66 (100)63 (95.45)63 (95.45)58 (87.88)32 (48.48)21 (31.82)17 (25.76)7 (10.61)Levofloxacin (59)58 (98.31)56 (94.92)58 (98.31)50 (84.75)24 (40.68)21 (35.59)15 (25.42)6 (10.17)Piperacillin (58)56 (96.55)55 (94.82)55 (94.82)53 (91.37)26 (44.82)17 (29.31)16 (27.50)5 (8.62)Cefoperazone (51)51 (100)50 (98.04)49 (96.07)45 (88.24)25 (49.02)14 (27.45)12 (23.53)3 (5.88)Gentamicin (51)49 (96.08)47 (92.16)48 (94.12)44 (86.27)21 (41.18)16 (31.37)12 (23.53)3 (5.88)Kanamycin (39)37 (94.87)36 (92.31)35 (89.74)32 (82.05)19 (48.72)9 (23.08)8 (20.51)3 (7.69)Tobramycin (39)38 (97.44)36 (92.31)35 (89.74)36 (92.31)19 (48.72)5 (12.82)8 (20.50)3 (7.69)Chloramphenicol (33)32 (96.97)30 (90.91)29 (87.88)27 (81.82)13 (39.9)8 (24.24)10 (30.30)2 (6.06)Minocycline (33)31 (93.94)32 (96.97)30 (90.91)31 (93.94)17 (51.52)8 (24.24)11 (33.33)2 (6.06)Aztreonam (28)28 (100)28 (100)27 (96.43)26 (92.86)12 (42.86)7 (25.00)7 (25.00)2 (7.14)Ceftazidime (21)21 (100)21 (100)21 (100)19 (90.48)9 (42.86)6 (28.57)7 (33.33)1 (4.76)Cefoxitin (17)15 (88.23)15 (88.23)12 (70.59)13 (76.47)9 (52.94)6 (35.29)2 (11.76)2 (11.76)Amikacin (8)7 (87.50)6 (75.00)7 (87.50)4 (50.00)5 (62.50)1 (12.50)1 (12.50)0 (0)Ertapenem (3)3 (100)3 (100)3 (100)2 (66.67)1 (33.33)1 (33.33)2 (66.67)1 (33.33)

Discussion {#S0004}
==========

*E. coli* strains are the most commonly isolated bacteria in hospitals.[@CIT0018]--[@CIT0020] Although these strains have been frequently reported in hospitals in western China, data regarding the virulence genes present in these strains are limited.[@CIT0009]--[@CIT0013] Thus, in this study, we investigated the presence of virulence genes and antimicrobial resistance in *E. coli* strains at a hospital in the western region of China in order to further expand our knowledge of the characteristics of *E. coli* strains prevalent in China.

We first detected 12 adherence and 27 virulence genes in 97 clinical *E. coli* isolates. Our results showed that most of the *E. coli* isolates contained multiple and heterogeneous virulence genes ([Table 2](#T0002){ref-type="table"}). Type 1 fimbriae is an *E. coli* adhesion factor encoded by the *fimC* and *fimH* genes. It enables *E. coli* to bind to intestinal epithelial cells by attaching on mannose-containing receptors. In our study, *fimC* and *fimH* were identified in 93.81 and 91.75% of the strains, respectively. Nuesch-Inderbinen et al[@CIT0021] detected the presence of *fimC* and *fimH* in all human *E. coli* strains isolated in Switzerland, while Malekzadegan and Khashei[@CIT0022] found *fimH* in all isolates from Iranian patients. These reports are in agreement with our findings; the high frequency of occurrence of *fimC* and *fimH* among *E. coli* strains points to their importance in *E. coli* adhesion.

Some *E. coli* strains, contain another type of fimbria, long polar fimbriae (LPF), encoded by the conserved gene *lpfA*.[@CIT0023],[@CIT0024] We found that 41.24% of the *E. coli* isolates carried *lpfA*, which is similar to the frequency (50%) reported in Mexico.[@CIT0025] Initial studies conducted on human biopsy samples have suggested that adherence and the attaching and effacing lesion caused by *E. coli* do not require LPF.[@CIT0024] Therefore, it is possible that LPF are not necessary for *E. coli* pathogenicity.

The High-Pathogenicity Island (HPI) marker genes, *irp2* and *fyuA*, were detected in 92.78 and 84.54%, respectively, of *E. coli* isolates in this study. The *irp2* and *fyuA* genes have been detected in a number of studies examining pathogenic *E. coli* isolated from humans,[@CIT0026]--[@CIT0028] similar to the results of the present study. The iron-uptake system of highly pathogenic strains is mediated via yersiniabactin, which is encoded by *irp2* and *fyuA* and is associated with strain virulence.[@CIT0029],[@CIT0030] A considerable number of bacteria isolated from food harbor *irp*2 and *fyu*A (involved in iron capture systems).[@CIT0031],[@CIT0032] This could be the reason for the frequent detection of *irp2* and *fyuA* in pathogenic *E. coli* isolated from humans.

The *hlyA* gene was detected in 32.99% of the *E. coli* isolates. In Iran, Malekzadegan and Khashei[@CIT0022] reported that 28.6% of the *E. coli* strains were positive for *hlyA*, whereas Dale et al[@CIT0033] found that 26% of *E. coli* strains in the UK carried *hlyA*, and Bozcal et al[@CIT0034] identified this gene in 15.4% of *E. coli* strains in Turkey. The percentage of *E. coli* harboring *hlyA* in our study was higher than detected in the above-mentioned studies. α-hemolysin (HlyA) belongs to a group of pore-forming leukotoxins containing RTX repeats, and is thus consider a virulence factor in *E. coli*.[@CIT0035]--[@CIT0037] Depending on its concentration and the type of cell affected, HlyA either displays cytolytic activity or hijacks innate immune signaling pathways.[@CIT0037]--[@CIT0039] The high percent of *hlyA* in this study suggests that HlyA is involved in the mechanisms underlying *E. coli* pathogenicity in 32 (32.99%) patients.

The *sat* gene was detected in 28.86% of *E. coli* isolates. Sat is frequently detected in pathogenic *E. coli* strains.[@CIT0005],[@CIT0040],[@CIT0041] As demonstrated by Guignot et al,[@CIT0042] Sat can cause tight junction lesions between epithelial cells, which may lead to an increase in their permeability. These findings indicate that Sat probably plays a role in *E. coli* pathogenesis in 28 (28.86%) of the patients.

The *cnf1* gene was found in seven (7.22%) *E. coli* isolates, similar to the 7.2% reported in Turkey.[@CIT0034] Moreover, Bouzari et al[@CIT0043] reported that 29.4% of *E. coli* strains harbor *cnf1* genes. Cytotoxic necrotizing factor type 1 (CNF1) is a monomeric protein previously shown to effect rabbit skin cell necrosis and multinucleation of various cultured eukaryotic cells.[@CIT0044]--[@CIT0046] Our results are in agreement with the low occurrence of *cnf1* in *E. coli* strains.

We next examined the antimicrobial resistance of the 97 *E. coli* strains. The *E. coli* isolates were insensitive to first-line antibiotics such as nalidixic acid, sulfonamide, ticarcillin, ampicillin, tetracycline, doxycycline, ofloxacin, cefotaxime, ciprofloxacin, and levofloxacin ([Table 3](#T0003){ref-type="table"}). The antibiotic resistance rates of the *E. coli* isolates exceeded those reported in developing countries such as Brazil, Turkey, and Ghana.[@CIT0005],[@CIT0034],[@CIT0047] Moreover, the resistance rates observed in our study were higher than noted in the CHINET project.[@CIT0018]--[@CIT0020] Unexpectedly, we found that all *E. coli* isolates were MDR and over half of them were resistant to \> 12 classes of antibiotics ([Table 4](#T0004){ref-type="table"} and [Figure 2](#F0002){ref-type="fig"}). These results highlight the increasing severity of antibiotic misuse in clinical practice in western China.

Carbapenem-resistant *Enterobacteriaceae* (CRE) are highly prevalent in China, the United States, Italy, Israel, Colombia, Greece, the Indian subcontinent, North Africa, and Turkey.[@CIT0048],[@CIT0049] China (especially the regions of Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hebei, Hong Kong, and Zhengzhou) is thought to be one of main endemic regions of these bacteria around the world.[@CIT0050],[@CIT0051] In our study, we found that three (3.09%) CRE among the 97 *E. coli* isolates were resistant to ertapenem ([Table 3](#T0003){ref-type="table"}). Carbapenem-resistant *E. coli* have been frequently reported in western China in recent years;[@CIT0052]--[@CIT0054] most probably owing to the use of carbapenems as antimicrobial agents in this region.

Lastly, but most importantly, we found that the *E. coli* strains harbor a high rate of virulence genes in addition to high antimicrobial resistance ([Table 5](#T0005){ref-type="table"}). These findings explain how the *E. coli* isolates are able to successfully invade the human body and evade antibiotic treatment. Our findings indicate that clinical MDR *E. coli* isolates harbor a high frequency of virulence genes and that their virulence gene profiles are highly heterogeneous. Therefore, surveillance and control measures need to be enhanced to prevent these isolates from spreading further in hospitals.

Conclusions {#S0005}
===========

This study demonstrates a high frequency of occurrence and heterogeneity of virulence gene profiles among clinical multidrug resistant *E. coli* isolates. We conclude that appropriate surveillance and control measures are essential to prevent the further spread of these isolates in hospitals. However, further investigations are needed including additional hospitals in western China and a greater number of *E.coli* isolates to better understand the prevalence of virulence genes and antimicrobial resistance of the *E.coli* in western China.
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